UroMems, a France-based global company developing implantable mechatronics technology to treat stress urinary incontinence (SUI), has raised a US$60m investment from US PE firm Ajax Health. It is the largest fundraising round to date for the company.
The investment provides continuing support for large-scale pivotal clinical trials of the firm’s UroActive implant in the US and France ahead of regulatory submission. UroActive is the first smart automated artificial urinary sphincter (AUS) to treat SUI.
“Combining our industry experience and capital with the UroMems team, we believe that the UroActive smart implant has the potential to become the standard of care for SUI treatment,” said David Beylik, partner at Ajax Health.
The latest investment builds upon the momentum of a US$47m Series C financing completed in June 2024, led by Crédit Mutuel Innovation with participation from the European Innovation Council and existing investors Wellington Partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners and Financière Arbevel. In 2020, the firm raised €16m in a Series B.
“Ajax Health Fund I’s support strengthens our position as we approach the pivotal points of FDA PMA submission and commercialisation,” said Hamid Lamraoui, co-founder and CEO of UroMems.
Ajax’s Beylik and Jeremy Durack are joining the UroMems board of directors.
